Langer Tom N, Wiech Thorsten, Noriega Mercedes, Biniaminov Sergey, Huber Tobias B, Fischer Lutz, Grahammer Florian, Kluger Malte A
III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
University Transplant Center (UTC), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Transpl Int. 2025 Jun 2;38:14153. doi: 10.3389/ti.2025.14153. eCollection 2025.
To address the shortage of organs for kidney transplantation, the Eurotransplant Senior Program (ESP) was established to enhance kidney allocation from elderly donors. This study aimed to evaluate post-transplant outcomes of deceased donor grafts and identify prognostic factors within the ESP population. We therefore analyzed patient data from 64 ESP recipients and their donors transplanted at our center between 2017 and 2022. Time-zero biopsies were analyzed using AI image analysis software for glomerular density and glomerulosclerosis. One-year patient and allograft survival rates were 96.9% and 85.9%. 5-year survival rate was 74.6%, as opposed to about 41.0% historically reported for patients on dialysis. Delayed Graft Function occurred in 29.7% of cases, with recipient coronary heart disease, BMI-disparities, and prolonged cold ischemia time as major predictors ( < 0.05). Histopathological analysis revealed that the degree of glomerulosclerosis and interstitial fibrosis and tubular atrophy (IFTA) were associated with graft failure in multivariable analyses ( < 0.05). Arteriolosclerosis (arteriolar hyalinosis) correlated with a higher risk for primary non-function ( < 0.05). The number of HLA mismatches was not significantly associated with graft outcome. Including prognostic baseline characteristics as well as histopathological AI analysis into individual allocation decisions during organ-acceptance process might improve allograft survival within the ESP and should prospectively be studied.
为了解决肾移植器官短缺的问题,欧洲移植高级项目(ESP)得以设立,以增加老年供体的肾脏分配。本研究旨在评估已故供体移植物的移植后结局,并确定ESP人群中的预后因素。因此,我们分析了2017年至2022年期间在我们中心接受移植的64例ESP受者及其供体的患者数据。使用人工智能图像分析软件对零时间活检组织进行肾小球密度和肾小球硬化分析。患者和移植物的1年生存率分别为96.9%和85.9%。5年生存率为74.6%,而历史报道的透析患者5年生存率约为41.0%。29.7%的病例发生了移植肾功能延迟恢复,主要预测因素为受者冠心病、体重指数差异和冷缺血时间延长(<0.05)。组织病理学分析显示,在多变量分析中,肾小球硬化程度以及间质纤维化和肾小管萎缩(IFTA)与移植物失败相关(<0.05)。小动脉硬化(小动脉玻璃样变)与原发性无功能风险较高相关(<0.05)。HLA错配数与移植物结局无显著相关性。在器官接受过程中将预后基线特征以及组织病理学人工智能分析纳入个体分配决策,可能会提高ESP内移植物的生存率,应进行前瞻性研究。